Metformin has a well-known downside: it lowers vitamin B12. B12 is a nutrient your brain needs, which makes this awkward for a drug that longevity researchers keep eyeing as a possible neuroprotector. A new NHANES analysis in Diabetes, Obesity and Metabolism asked whether the B12 dip cancels out any brain benefit. In this dataset, it didn't.
The findings are intriguing, but they are observational. They show an association, not proof that metformin protects the brain.
The paradox: lower B12, better scores
The researchers, from Texas Tech University, analysed NHANES 2011-2014 data on 587 US adults aged 60 and older with type 2 diabetes. Of these, 408 took metformin and 179 took other non-insulin diabetes drugs. The comparison group matters. Comparing metformin users with other diabetes patients is more informative than comparing them with healthy people, because everyone in the sample has the same disease.
The headline numbers:
- Serum B12: 569.3 pg/mL in metformin users vs. 825.3 pg/mL in the comparison group (p = 0.026)
- Digit Symbol Substitution Test (DSST): 47.5 vs. 39.5 (p < 0.001) in unadjusted comparisons. The DSST is a common test of processing speed, attention and executive function.
So the metformin group had less B12 but higher cognitive scores.
After adjustment, the signal shrank but held up
The raw gap overstates things, because metformin users may differ from other patients in age, education, kidney function and disease severity. After full adjustment, the metformin group scored 3.75 points higher on the DSST. The 95% confidence interval ran from -0.06 to 7.55 (p = 0.053), which is borderline. With multiple imputation for missing data, the estimate was β = 3.49 (p = 0.006).
That is suggestive, not definitive. The primary adjusted result sits right at the edge of statistical significance, and the authors describe their approach as exploratory.
The B12 plot twist
The obvious worry was that B12 depletion would offset metformin's benefits. The team tested whether B12 and methylmalonic acid (MMA) mediated the link between metformin and cognition. MMA is a metabolic marker that tends to rise when functional B12 status is poor. They ran four statistical frameworks: bootstrap mediation, parallel mediation, structural equation modeling and weighted quantile sum regression.
About 95.1% of the association was direct, meaning it was independent of B12 and MMA. In other words, B12 and MMA did not statistically explain the cognitive difference.
This does not show that B12 doesn't matter for the brain. It shows that in this sample, B12 and MMA levels weren't what linked metformin use to DSST scores. The data are also cross-sectional, so they can't show how B12 and cognition change over time in people on long-term metformin.
Who seemed to benefit most
The association wasn't uniform:
- Ages 60-69: The benefit was concentrated in this "younger-old" group (interaction p = 0.003).
- Lower DSST quantiles: People with weaker baseline cognitive performance showed more of the difference, which suggests cognitively vulnerable subgroups may be where the association is strongest.
One caution applies to both patterns. Subgroup findings are more likely to be statistical flukes, and they need replication.
Why it can't prove metformin boosts the brain
Be skeptical of any "metformin makes you smarter" headline built on this study.
- It's observational. NHANES is a snapshot. It can't establish that metformin caused better scores.
- Confounding is likely. Doctors may prescribe metformin to patients who are healthier overall, with better kidney function, milder disease and fewer complications. Those factors also affect cognition.
- Causal mediation methods have limits. The authors call their analysis exploratory, and these methods depend on assumptions that observational data can't fully verify.
- There's one cognitive test. The DSST is useful but narrow. It doesn't measure dementia risk.
- Everyone in the sample has diabetes. The results say nothing about metformin use in healthy people for longevity.
Practical takeaways
Dose and timing: The paper doesn't analyse dose, duration or timing, so there is no evidence-based number to extract. Metformin is prescription-only, and any dosing decision belongs with a physician.
Who this is relevant for: Older adults with type 2 diabetes who are already prescribed metformin, especially those in their 60s. The finding is mildly reassuring. It doesn't suggest the B12 drop is wiping out cognitive benefit, though it doesn't make the drop harmless.
Who it is not for: Healthy biohackers. Nothing here supports taking metformin as an off-label brain or longevity booster. The study didn't test non-diabetic people.
Monitor your B12 anyway: Metformin lowering B12 is established, and B12 deficiency can cause anemia and neuropathy. If you take metformin, ask your clinician about periodic B12 testing. MMA is sometimes used when B12 results are borderline. Supplementation, if needed, should follow lab results and medical advice.
The bottom line
In a nationally representative sample of older adults with type 2 diabetes, metformin users had lower B12 but better processing-speed scores. B12 and MMA didn't statistically explain the gap. It's an interesting hypothesis-generating result for researchers studying metformin and brain aging, but it needs prospective studies and trials before anyone treats it as a cognitive intervention.